Related Experiment Video
Updated: Jun 13, 2026
07:35
Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice
Published on: January 26, 2024
The oral hypoglycemics: boon or bane?
Summary
The University Group Diabetes Program (UGDP) study on oral hypoglycemic agents faced scrutiny. This review examines the UGDP findings and offers treatment suggestions for adult-onset diabetes.
Area of Science:
- Endocrinology and Metabolism
- Clinical Trial Analysis
- Diabetes Mellitus Research
Background:
- The University Group Diabetes Program (UGDP) study investigated oral hypoglycemic agents.
- Subsequent re-evaluation by the Biometric Society led to widespread debate regarding this diabetes therapy.
- The study's findings have been both attacked and defended globally, highlighting their controversial nature.
Purpose of the Study:
- To review the fundamental findings of the UGDP study.
- To critically comment on the data presented in the UGDP study.
- To provide evidence-based treatment recommendations for adult-onset diabetes.
Main Methods:
- Review of existing UGDP study data.
- Critical analysis of the UGDP study's statistical and clinical interpretations.
- Synthesis of findings to inform clinical practice guidelines.
Main Results:
- The UGDP study reported specific outcomes related to oral hypoglycemic agents.
- The data analysis and interpretation have been subjects of ongoing scientific discussion.
- Controversies surrounding the UGDP study impact current understanding of diabetes management.
Conclusions:
- The UGDP study's conclusions regarding oral hypoglycemic agents remain debated.
- A critical appraisal of the UGDP data is essential for informed clinical decision-making.
- Treatment strategies for adult-onset diabetes should consider the implications of the UGDP findings.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...